325 related articles for article (PubMed ID: 22095692)
1. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
[TBL] [Abstract][Full Text] [Related]
2. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
Chandra A; Sharma A; Calingasan NY; White JM; Shurubor Y; Yang XW; Beal MF; Johri A
Hum Mol Genet; 2016 Jun; 25(11):2269-2282. PubMed ID: 27008868
[TBL] [Abstract][Full Text] [Related]
3. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
[TBL] [Abstract][Full Text] [Related]
4. Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease.
Chen LW; Horng LY; Wu CL; Sung HC; Wu RT
Neuropharmacology; 2012 Sep; 63(4):719-32. PubMed ID: 22633948
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
6. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.
Wenz T; Diaz F; Spiegelman BM; Moraes CT
Cell Metab; 2008 Sep; 8(3):249-56. PubMed ID: 18762025
[TBL] [Abstract][Full Text] [Related]
7. PGC-1α, mitochondrial dysfunction, and Huntington's disease.
Johri A; Chandra A; Flint Beal M
Free Radic Biol Med; 2013 Sep; 62():37-46. PubMed ID: 23602910
[TBL] [Abstract][Full Text] [Related]
8. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.
Ho DJ; Calingasan NY; Wille E; Dumont M; Beal MF
Exp Neurol; 2010 Sep; 225(1):74-84. PubMed ID: 20561979
[TBL] [Abstract][Full Text] [Related]
10. Impaired PGC-1alpha function in muscle in Huntington's disease.
Chaturvedi RK; Adhihetty P; Shukla S; Hennessy T; Calingasan N; Yang L; Starkov A; Kiaei M; Cannella M; Sassone J; Ciammola A; Squitieri F; Beal MF
Hum Mol Genet; 2009 Aug; 18(16):3048-65. PubMed ID: 19460884
[TBL] [Abstract][Full Text] [Related]
11. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
[TBL] [Abstract][Full Text] [Related]
12. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.
Yatsuga S; Suomalainen A
Hum Mol Genet; 2012 Feb; 21(3):526-35. PubMed ID: 22012983
[TBL] [Abstract][Full Text] [Related]
13. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
Chiang MC; Chern Y; Juo CG
Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
[TBL] [Abstract][Full Text] [Related]
14. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
Hathorn T; Snyder-Keller A; Messer A
Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
[TBL] [Abstract][Full Text] [Related]
16. Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function.
Romanino K; Mazelin L; Albert V; Conjard-Duplany A; Lin S; Bentzinger CF; Handschin C; Puigserver P; Zorzato F; Schaeffer L; Gangloff YG; Rüegg MA
Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20808-13. PubMed ID: 22143799
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) deacetylation by physical activity: intact adipocytokine signaling is required.
Li L; Pan R; Li R; Niemann B; Aurich AC; Chen Y; Rohrbach S
Diabetes; 2011 Jan; 60(1):157-67. PubMed ID: 20929977
[TBL] [Abstract][Full Text] [Related]
18. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
[TBL] [Abstract][Full Text] [Related]
19. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.
Viscomi C; Bottani E; Civiletto G; Cerutti R; Moggio M; Fagiolari G; Schon EA; Lamperti C; Zeviani M
Cell Metab; 2011 Jul; 14(1):80-90. PubMed ID: 21723506
[TBL] [Abstract][Full Text] [Related]
20. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
